# AATD Patient Registry & Research Database

**Document Version**: 1.0
**Last Updated**: November 8, 2025
**Owner**: Chief Research Officer
**Purpose**: Establish comprehensive database of AATD patients to accelerate research, enable clinical trial recruitment, track disease outcomes, and improve understanding of AATD natural history

---

## ğŸ“‹ Table of Contents

1. [Registry Overview](#registry-overview)
2. [Why a Patient Registry Matters](#why-a-patient-registry-matters)
3. [Data Collection](#data-collection)
4. [Registry Uses](#registry-uses)
5. [Clinical Trial Recruitment](#clinical-trial-recruitment)
6. [Research Access](#research-access)
7. [Patient Benefits](#patient-benefits)
8. [Implementation Plan](#implementation-plan)
9. [Success Metrics](#success-metrics)

---

## Registry Overview

### What We Offer

**Mark Egly Foundation AATD Patient Registry** is a confidential, secure database collecting comprehensive health information from AATD patients to:

**Registry Purposes**:

- âœ… **Accelerate Research**: Provide researchers with large-scale patient data (genetics, lung function, treatments, outcomes)
- âœ… **Clinical Trial Recruitment**: Connect patients with trials they're eligible for (fast recruitment = faster cures)
- âœ… **Natural History Studies**: Track disease progression (identify patterns, predict outcomes, improve treatment)
- âœ… **Real-World Evidence**: Show what works (augmentation therapy effectiveness, treatment adherence, quality of life)
- âœ… **Health Equity**: Identify disparities (rural vs. urban outcomes, minority access to care)

**What We Collect**:

- Demographics (age, sex, race, geography)
- Genetics (genotypeâ€”ZZ, SZ, MZ, rare variants)
- Lung function (FEV1, DLCO, CT scansâ€”track decline)
- Liver disease (enzymes, imaging, biopsy results)
- Treatments (augmentation therapy, inhalers, oxygen, transplant)
- Outcomes (hospitalizations, exacerbations, mortality, quality of life)

**Enrollment**:

- **Voluntary**: Patients opt-in (consent required)
- **Free**: No cost to participate
- **Confidential**: Data de-identified (researchers don't see names, only ID numbers)
- **Secure**: HIPAA-compliant (encrypted, password-protected)

**Who Can Join**:

- AATD patients (any genotypeâ€”ZZ, SZ, MZ, rare variants)
- Any age (pediatric, adult)
- Any stage (newly diagnosed, advanced disease, post-transplant)
- Any location (US, international)

---

### Registry Goals

**Year 1** (2026):

- 1,000 patients enrolled
- 50 data elements collected (per patient)
- 10 research projects using registry data
- 5 clinical trials recruiting from registry

**Year 3** (2028):

- 10,000 patients enrolled (50% of US AATD patients)
- 100 data elements collected
- 50 research projects
- 20 clinical trials

**Year 5** (2030):

- 25,000 patients enrolled (includes international)
- Integration with EHR (electronic health recordsâ€”auto-populate data from patient's medical record)
- Real-time data (continuously updatedâ€”not just annual surveys)
- Premier AATD research resource (cited in 100+ publications/year)

---

## Why a Patient Registry Matters

### Current Research Limitations

**Problem**: AATD is rare (1 in 2,500) â†’ small patient populations â†’ hard to study

**Consequences**:

- âŒ **Clinical trials take years to enroll** (need 100+ patients, but AATD Centers see only 50-100 patients totalâ€”recruiting nationwide takes 2-5 years)
- âŒ **Natural history unknown** (don't know how fast disease progresses, which patients decline fastest, why some patients stable for decades while others need transplant in 5 years)
- âŒ **Treatment gaps** (don't know optimal age to start augmentation, whether SZ patients benefit, if inhaled AAT works)
- âŒ **Disparities hidden** (don't track outcomes by race, geography, incomeâ€”can't address inequities)

---

### How Registries Accelerate Research

**Examples from Other Diseases**:

**Cystic Fibrosis Foundation Patient Registry** (established 1966):

- Tracks 30,000+ CF patients (90% of US CF population)
- Data collected annually (lung function, treatments, complications)
- **Impact**:
  - Identified best treatments (Trikafta approvalâ€”registry data showed efficacy)
  - Improved survival (median survival age: 10 years in 1960s â†’ 47 years todayâ€”registry data guided treatment improvements)
  - 100+ publications/year using registry data

**Michael J. Fox Foundation Parkinson's Registry**:

- Tracks 50,000+ Parkinson's patients
- Enabled 200+ clinical trials (fast recruitmentâ€”contact patients by email, enroll in weeks vs. years)
- Identified biomarkers (predict disease progression)

**AATD Can Do the Same**â€”but we need the registry first.

---

### Current AATD Registries (Inadequate)

**Alpha-1 Foundation Research Registry**:

- Established 1997
- ~3,000 patients enrolled
- **Limitations**:
  - Only 15% of US AATD patients enrolled (low penetration)
  - Data collected once (at enrollmentâ€”no longitudinal follow-up)
  - Limited data elements (~30â€”need 100+ for comprehensive research)
  - No EHR integration (patients manually enter dataâ€”inaccurate, incomplete)

**Medical University of South Carolina (MUSC) AATD Registry**:

- ~2,500 patients
- Similar limitations (one-time enrollment, limited follow-up)

**Mark Egly Foundation Registry Will Be Superior**:

- âœ… **Larger**: Goal 25,000 patients (10x current registries)
- âœ… **Longitudinal**: Annual updates (track disease progression over time)
- âœ… **Comprehensive**: 100+ data elements (genetics, lung, liver, treatments, outcomes, quality of life)
- âœ… **EHR-Integrated**: Auto-populate from medical records (accurate, complete, real-time)

---

### Patient Stories

**Story 1: Clinical Trial Recruitment**:

- **Before Registry**: Gene therapy trial needs 50 ZZ patients (FEV1 40-60%, age 30-50). Took 3 years to recruit (researchers contacted AATD centers, centers screened patients 1-by-1â€”slow, expensive).
- **With Registry**: Search registry database (filter: ZZ, FEV1 40-60%, age 30-50) â†’ identify 200 eligible patients â†’ email patients â†’ 50 enrolled in 3 months (20x faster)

**Story 2: Natural History Study**:

- **Before Registry**: Researcher wants to study lung function decline in SZ patients (do SZ patients need augmentation therapy?). No data available (most studies only include ZZâ€”SZ patients excluded). Can't answer question.
- **With Registry**: Query registry (filter: SZ, lung function data) â†’ analyze 500 SZ patients â†’ find that 20% of SZ patients with FEV1 < 50% decline as fast as ZZ â†’ **New Discovery**: Some SZ patients may benefit from augmentation therapy (change clinical practice)

**Story 3: Health Equity**:

- **Before Registry**: No data on racial disparities in AATD (most research on white patientsâ€”minorities underrepresented).
- **With Registry**: Analyze 10,000 patients by race â†’ **Discovery**: Black AATD patients diagnosed 5 years later than white patients (doctors less likely to test), have worse outcomes (FEV1 10% lower at diagnosis). Foundation launches targeted screening program (Black communities) â†’ earlier diagnosis â†’ better outcomes.

---

## Data Collection

### Enrollment Process

**Step 1: Patient Consents**:

- Go to MarkEglyFoundation.org/Registry OR call 1-800-AATD-REG
- Read consent form (explains what registry is, how data used, privacy protections)
- E-sign consent (HIPAA authorizationâ€”allow registry to access medical records)

**Step 2: Baseline Survey** (30-45 minâ€”complete at enrollment):

- **Demographics**: Age, sex, race/ethnicity, zip code, education, income
- **AATD Diagnosis**: Genotype (ZZ, SZ, MZ, rare), AAT level, age at diagnosis, family history
- **Lung Disease**: FEV1, DLCO, CT scan results (emphysema, bronchiectasis), symptoms (dyspnea scale), exacerbations (# per year), hospitalizations
- **Liver Disease**: Liver enzymes (AST, ALT), imaging (ultrasound, FibroScan), biopsy results, cirrhosis
- **Treatments**: Augmentation therapy (brand, start date, frequency, adherence), inhalers (type, frequency), oxygen (flow rate, hours/day), transplant (lung, liver, date)
- **Comorbidities**: Smoking history (pack-years), COPD, asthma, bronchiectasis, liver disease, panniculitis, vasculitis
- **Quality of Life**: SF-36 survey (physical function, mental health, pain, energy)
- **Healthcare Access**: Insurance type, distance to specialist, # of doctor visits/year

**Step 3: Medical Records Release**:

- Patient authorizes registry to request medical records (from pulmonologist, hepatologist, PCP)
- Registry staff reviews records (extract dataâ€”lung function tests, lab results, imaging, hospitalizations)
- Data entered into registry database (de-identifiedâ€”patient assigned ID number)

**Step 4: Annual Follow-Up**:

- Every 12 months, patient receives email/phone call (update information)
- Short survey (15 minâ€”any changes? New treatments? Hospitalizations? Lung function tests?)
- Medical records updated (registry requests new records from doctors)

**Ongoing**:

- Patients can update anytime (report new diagnosis, treatment change, hospitalization)
- Registry sends reminders (email, textâ€”"Time for your annual update!")

---

### Data Elements (100+ Collected)

**Demographics** (10 elements):

- Age, sex, race, ethnicity, zip code, education level, income, employment status, insurance type, marital status

**Genetics** (15 elements):

- Genotype (ZZ, SZ, MZ, MS, SS, rare variants), AAT level, genetic test date, genetic counseling received, family history (# of relatives with AATD), carrier status (for SZ, MZ), genetic testing method (blood test, genetic sequencing)

**Lung Disease** (30 elements):

- FEV1 (% predicted), DLCO (% predicted), FEV1/FVC ratio, 6-minute walk distance, oxygen saturation (SpO2), CT scan results (emphysema distribution, severity, bronchiectasis, air trapping), symptoms (dyspnea scaleâ€”mMRC, CAT score), exacerbations (# per year, severityâ€”hospitalization vs. outpatient), hospitalizations (# per year, ICU admissions, mechanical ventilation), lung function decline rate (%/year)

**Liver Disease** (20 elements):

- Liver enzymes (AST, ALT, alkaline phosphatase, bilirubin, albumin), liver imaging (ultrasound, FibroScan, MRIâ€”results), liver biopsy (fibrosis stage, steatosis, inflammation), cirrhosis (yes/no, Child-Pugh score, MELD score), portal hypertension, varices, ascites, hepatocellular carcinoma

**Treatments** (25 elements):

- Augmentation therapy (yes/no, brandâ€”Prolastin, Aralast, Zemaira, Glassia, start date, frequencyâ€”weekly/biweekly, adherenceâ€”% of infusions received, side effects, discontinuation reason), inhalers (bronchodilatorsâ€”type, frequency; steroidsâ€”type, frequency), oxygen therapy (yes/no, flow rate, hours/day, continuous vs. PRN, start date), pulmonary rehab (yes/no, completion), lung transplant (yes/no, date, single vs. double, complications, rejection episodes, survival), liver transplant (yes/no, date, complications)

**Lifestyle** (10 elements):

- Smoking history (never, former, current; pack-years; quit date), alcohol use (drinks/week), exercise (minutes/week, type), diet (quality score), vaccinations (flu, pneumonia, COVIDâ€”up to date?), environmental exposures (occupational dust, fumes, chemicals), air quality (at homeâ€”zip code pollution index)

**Comorbidities** (15 elements):

- COPD, asthma, bronchiectasis, chronic bronchitis, lung cancer, panniculitis (AATD skin disease), vasculitis, hepatitis C, autoimmune disease, cardiovascular disease (heart attack, stroke, heart failure), diabetes, kidney disease, osteoporosis, depression/anxiety

**Quality of Life** (10 elements):

- SF-36 (physical function, role limitations, pain, general health, vitality, social function, emotional role, mental health), EQ-5D (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), COPD assessment test (CAT score), dyspnea scale (mMRC), fatigue scale

**Healthcare Utilization** (10 elements):

- # of PCP visits/year, # of pulmonologist visits/year, # of hepatologist visits/year, # of ER visits/year, # of hospitalizations/year, # of ICU admissions/year, distance to specialist (miles), telemedicine visits (yes/no, frequency), home health services (yes/no), hospice (yes/no)

**Research Participation** (5 elements):

- Clinical trials (yes/no, trial name, phase, outcome), research studies (yes/no, study type), biobank (yes/noâ€”donated blood, tissue), genetic studies (yes/noâ€”whole genome sequencing), drug development (yes/noâ€”helped develop new therapy)

---

### Data Security & Privacy

**HIPAA-Compliant**:

- All data encrypted (AES-256 encryptionâ€”military-grade)
- Secure servers (AWS GovCloudâ€”government-certified)
- Password-protected (multi-factor authentication for registry staff)
- Access controls (only authorized personnel see dataâ€”researchers get de-identified data)

**De-Identification**:

- Patients assigned ID numbers (researchers never see names, addresses, birthdates)
- Geographic data aggregated (zip code â†’ regionâ€”can't identify small towns)
- Dates shifted (to prevent re-identificationâ€”e.g., diagnosis date Â± 1 year)

**Data Use Agreements**:

- Researchers sign agreements (promise to protect data, not re-identify patients, publish results)
- Annual audits (ensure compliance)

---

## Registry Uses

### 1. Natural History Studies

**Goal**: Understand how AATD progresses over time

**Questions Registry Can Answer**:

- How fast does lung function decline in ZZ vs. SZ vs. MZ patients?
- What predicts rapid decline (genetics, smoking, environmental factors)?
- At what FEV1 do patients typically develop respiratory failure (need transplant)?
- Does augmentation therapy slow decline (real-world dataâ€”not just clinical trials)?

**Example Study**:

- Analyze 5,000 ZZ patients (10 years of data)
- **Findings**: Average FEV1 decline = 50 mL/year (without augmentation), 30 mL/year (with augmentation) â†’ **Conclusion**: Augmentation therapy slows decline by 40%
- **Impact**: Stronger evidence for augmentation therapy â†’ more insurance approvals

---

### 2. Treatment Effectiveness (Real-World Evidence)

**Goal**: Show what works in real-world patients (not just clinical trial participants)

**Questions**:

- Does augmentation therapy improve survival (long-term, 20+ years)?
- Do inhalers improve symptoms (quality of life)?
- Does pulmonary rehab reduce hospitalizations?
- Which oxygen therapy regimen is best (continuous vs. PRN)?

**Example Study**:

- Compare 1,000 patients on augmentation therapy vs. 1,000 not on therapy (matched by FEV1, age, smoking)
- **Findings**: Augmentation patients live 5 years longer, have 50% fewer hospitalizations
- **Impact**: Publish in NEJM â†’ FDA approves label expansion (augmentation for SZ patients)

---

### 3. Biomarker Discovery

**Goal**: Identify blood tests, imaging markers that predict disease progression

**Questions**:

- Can we predict which patients will decline rapidly (before FEV1 drops)?
- Are there biomarkers for exacerbations (predict who will get hospitalized)?
- Can imaging (CT densitometry) replace FEV1 (more sensitive, earlier detection of progression)?

**Example Study**:

- Measure 50 blood biomarkers in 500 patients (at baseline, then track 5 years)
- **Findings**: High CRP + low albumin = 3x risk of rapid decline
- **Impact**: Doctors can identify high-risk patients earlier â†’ start augmentation therapy sooner

---

### 4. Health Equity Research

**Goal**: Identify and address disparities in AATD care

**Questions**:

- Are minority patients diagnosed later than white patients?
- Do rural patients have worse outcomes (less access to specialists)?
- Do low-income patients receive augmentation therapy (or skip due to cost)?

**Example Study**:

- Analyze 10,000 patients by race, income, geography
- **Findings**: Black patients diagnosed 5 years later, have 15% lower FEV1 at diagnosis (vs. white patients)
- **Impact**: Foundation launches targeted screening program (Black churches, community clinics) â†’ earlier diagnosis

---

### 5. Quality Improvement

**Goal**: Improve AATD care delivery

**Questions**:

- What % of AATD patients receive augmentation therapy (vs. should receive)?
- What % see pulmonologist annually (vs. PCP only)?
- What % get family testing (cascade testing)?

**Example Study**:

- Analyze 5,000 ZZ patients (FEV1 < 65%â€”augmentation indicated)
- **Findings**: Only 60% receive augmentation therapy (40% not receiving indicated treatment)
- **Impact**: Foundation launches education campaign (doctors + patients) â†’ increase treatment rate to 80%

---

## Clinical Trial Recruitment

### Fast Recruitment Pipeline

**Problem**: Clinical trials take years to enroll (slow, expensive, delays new treatments)

**Solution**: Registry = pre-screened patient pool (researchers can contact eligible patients instantly)

---

### How It Works

**Step 1: Trial Posts Eligibility Criteria**:

- Researcher contacts Foundation (want to recruit for gene therapy trial)
- Criteria: ZZ genotype, FEV1 40-60%, age 30-50, no liver disease, non-smoker

**Step 2: Registry Searches Database**:

- Query registry (filter by criteria)
- Identify 200 eligible patients (from 10,000 in registry)

**Step 3: Contact Patients**:

- Send email to 200 patients (trial invitationâ€”brief description, eligibility, how to enroll)
- Interested patients click link â†’ screened by trial site (confirm eligibility)
- 50 patients enrolled (3 monthsâ€”vs. 3 years traditional recruitment)

**Step 4: Track Outcomes**:

- Registry follows trial participants (collect outcomesâ€”did trial help?)
- Long-term follow-up (after trial endsâ€”track survival, lung function 5-10 years post-treatment)

---

### Benefits for Trials

**Faster Recruitment**: 3 months vs. 3 years (10x faster)

**Cost Savings**: Traditional recruitment costs $5K-$10K per patient (advertising, screening, travel reimbursement). Registry recruitment: $500 per patient (just email, screening)â€”90% cost reduction

**Better Enrollment**: Higher % of contacted patients enroll (registry patients pre-consented, motivated to participate in research)

**Diverse Enrollment**: Registry tracks race, geography â†’ can recruit minorities, rural patients (improve trial diversityâ€”FDA priority)

---

### Year 1 Goal: 5 Trials Recruit from Registry

**Target Trials**:

- Gene therapy (AAV, CRISPR)
- Inhaled AAT (easier than IV)
- Anti-fibrotic drugs (for liver disease)
- Biomarker studies (predict decline)
- Quality of life interventions (pulmonary rehab, mental health)

---

## Research Access

### Data Request Process

**Step 1: Researcher Submits Proposal**:

- Fill out form (research question, methods, data needed, publications planned)
- IRB approval (ethics board approves study)

**Step 2: Foundation Reviews**:

- Scientific review (is study valid, important?)
- Privacy review (does researcher need identifiable data, or de-identified OK?)
- Data use agreement (researcher signsâ€”promise to protect data)

**Step 3: Data Provided**:

- De-identified dataset (CSV, Excelâ€”patient ID numbers, no names)
- Data dictionary (explains variables, coding)
- Support (registry staff available for questions)

**Step 4: Publication**:

- Researcher publishes results
- Acknowledges Foundation registry (increase visibility, attract more patients to enroll)

---

### Data Access Tiers

**Tier 1: Summary Statistics** (Free, Public):

- Anyone can access (website dashboard)
- Aggregate data (e.g., "Average FEV1 of ZZ patients = 45%", "60% on augmentation therapy")
- No patient-level data (privacy-protected)

**Tier 2: De-Identified Dataset** (Free, Requires Approval):

- Researchers submit proposal (Foundation approves)
- Patient-level data (de-identifiedâ€”ID numbers only)
- For academic research (non-commercial)

**Tier 3: Identified Dataset** (Restricted):

- Requires IRB approval + patient consent (contact patients directly)
- For trials, longitudinal studies (need to follow patients over time)
- Commercial researchers (pharma) pay fee ($50K-$100Kâ€”fund registry operations)

---

### Year 1 Goal: 10 Research Projects

**Target Studies**:

- Natural history (FEV1 decline rates)
- Augmentation therapy effectiveness (real-world outcomes)
- SZ outcomes (do SZ patients need treatment?)
- Liver disease (prevalence, predictors, outcomes)
- Health equity (racial, geographic disparities)
- Biomarkers (predict progression)
- Quality of life (factors affecting QOL)
- Telemedicine (effectiveness in AATD care)
- Pulmonary rehab (adherence, outcomes)
- Clinical trial recruitment (feasibility, patient willingness)

---

## Patient Benefits

### Why Patients Should Join

**1. Advance Research**: Your data = cures (every patient enrolled = closer to gene therapy, inhaled AAT, better treatments)

**2. Get Matched to Clinical Trials**: Be contacted about trials you're eligible for (access cutting-edge therapiesâ€”gene therapy, new drugs)

**3. Receive Annual Health Summary**: Registry sends personalized report (your lung function trend, how you compare to other AATD patients, recommendations)

**4. Connect with Specialists**: Registry can refer you to AATD Centers of Excellence (if not seeing specialist)

**5. Support Family Testing**: Registry provides genetic counseling referrals (help family get testedâ€”cascade testing)

**6. Contribute to Knowledge**: Help future AATD patients (your participation = better care for next generation)

---

### Patient Testimonials

**"I joined the registry because I want my data to help find a cure. If researchers can use my information to develop gene therapy, it's worth it."**
â€” Sarah, 42, ZZ AATD

**"The registry matched me to a clinical trial that saved my life. I was enrolled in a gene therapy trialâ€”my lung function stabilized."**
â€” John, 55, ZZ AATD

**"I get an annual health report from the registry. It's helpful to see my lung function trend over time and compare to other patients."**
â€” Lisa, 38, SZ AATD

---

## Implementation Plan

### Phase 1: Platform Development (Months 1-6)

**Database Build**:

- REDCap (Research Electronic Data Captureâ€”secure, HIPAA-compliant, free for nonprofits)
- Customize (100 data elements, consent forms, surveys)
- EHR integration (connect to Epic, Cernerâ€”auto-populate data from medical recordsâ€”requires API agreements with EHR vendors)

**Consent & Enrollment System**:

- Online enrollment (e-consent, HIPAA authorization, baseline survey)
- Phone enrollment (for patients without internetâ€”staff-assisted)

**Data Management**:

- Hire data manager ($80K/yearâ€”oversee data collection, quality, security)
- Train staff (data entry, medical record review, patient contact)

---

### Phase 2: Pilot Launch (Months 7-12)

**Recruit 100 Patients** (Beta test):

- Foundation mailing list (10K patients)
- AlphaNet, Alpha-1 Foundation partnerships (co-promote registry)
- AATD Centers (ask doctors to refer patients)

**Collect Data**:

- Baseline surveys (100 patients complete)
- Medical records (request from 100 patients' doctors)
- Test data quality (identify errors, missing data, fix)

**Feedback**:

- Survey patients (satisfaction, suggestions)
- Refine process (simplify survey, improve consent form, streamline medical record requests)

---

### Phase 3: National Launch (Year 2)

**Marketing Campaign**:

- Email blast (10K patients)
- Social media (Facebook ads, patient groups)
- PR (press release, patient stories)
- Doctor outreach (ask specialists to encourage patients to enroll)

**Goal: 1,000 Patients Enrolled** (Year 1)

---

### Phase 4: Research Launch (Year 2+)

**First 10 Research Projects**:

- In-house studies (Foundation researchers analyze data)
- External grants (apply for NIH fundingâ€”registry data = strong application)
- Pharma collaborations (CSL Behring, Takedaâ€”sponsor studies, fund registry)

**Clinical Trial Recruitment**:

- Partner with 5 trials (recruit patients from registry)
- Track outcomes (how many patients enrolled, trial completion rates)

---

### Phase 5: EHR Integration (Year 3+)

**Connect to Electronic Health Records**:

- Partner with Epic, Cerner (largest EHR vendors)
- API integration (auto-pull lung function tests, lab results, hospitalizationsâ€”no manual data entry)
- Real-time updates (data refreshed continuously, not just annual surveys)

**Goal**: 50% of registry patients with EHR integration (Year 5)

---

## Success Metrics

### Track Quarterly

**Enrollment**:

- # of patients enrolled (total, per month)
- Demographics (age, genotype, geographyâ€”ensure diverse enrollment)
- Retention rate (% of patients completing annual follow-up)

**Data Quality**:

- Completeness (% of data elements collected per patient)
- Accuracy (audit medical recordsâ€”how often data entry errors?)
- Timeliness (how quickly data updatedâ€”goal: annual surveys completed within 2 weeks of reminder)

**Research Impact**:

- # of research projects using registry data
- # of publications citing registry
- # of clinical trials recruiting from registry
- # of patients matched to trials (and enrolled)

**Patient Satisfaction**:

- Enrollment survey (satisfaction with process)
- Annual survey (value of participation, would recommend to others)

---

### Year 1 Targets

**Enrollment**:

- 1,000 patients enrolled
- 50% ZZ, 30% SZ, 20% other genotypes (representative of AATD population)
- 80% retention (complete annual follow-up)

**Data**:

- 50 data elements collected (per patient)
- 90% completeness (per data element)

**Research**:

- 10 research projects using registry
- 5 clinical trials recruiting from registry
- 50 patients matched to trials

**Publications**:

- 5 publications citing registry (establish credibility)

---

## Summary

**Mark Egly Foundation AATD Patient Registry**:

- âœ… **Comprehensive Database**: 100+ data elements (genetics, lung, liver, treatments, outcomes, quality of life)
- âœ… **Accelerate Research**: Enable natural history studies, treatment effectiveness, biomarker discovery
- âœ… **Fast Clinical Trial Recruitment**: Match patients to trials (3 months vs. 3 years)
- âœ… **Patient Benefits**: Annual health summaries, trial matching, support research, free participation

**This registry will transform AATD research**:

- **Faster cures** (gene therapy, inhaled AATâ€”trials enroll quickly, results sooner)
- **Better treatments** (real-world evidence shows what works, FDA approvals based on registry data)
- **Health equity** (identify disparities, target interventions, ensure all AATD patients get best care)

**"Your data = cures. Join the registry today."**

---

**Ready to Enroll?**

**Mark Egly Foundation AATD Patient Registry**
ğŸ“ Phone: 1-800-AATD-REG
ğŸ“§ Email: registry@markeglyfoundation.org
ğŸŒ Website: MarkEglyFoundation.org/Registry

---

**Approved by**: Board of Directors
**Effective Date**: January 1, 2026
**Review Date**: Annually
**Version**: 1.0

---

_"Together, we can find a cure."_

**â€” Mark Egly Foundation**
